Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 7/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 5/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726056 | 0.90 | SLC6A4 (1.00) | SLC6A4MAPK1TSHRMPOGPR84 | |
| SCHEMBL8125191 | 0.82 | SLC6A4 (0.84) | SLC6A4MAPK1TSHRMPOGPR84 | |
| SCHEMBL26996488 | 0.82 | SLC6A4 (0.83) | SLC6A4MAPK1TSHRMPOGPR84 | |
| SCHEMBL5727535 | 0.80 | SLC6A4 (0.63) | SLC6A4MAPK1TSHRMPO | |
| SCHEMBL9635359 | 0.79 | SLC6A4 (0.79) | SLC6A4MAPK1GPR84 | |
| SCHEMBL9635299 | 0.79 | SLC6A4 (0.78) | SLC6A4MAPK1MPOGPR84 | |
| SCHEMBL10119871 | 0.78 | SLC6A4 (0.72) | SLC6A4MAPK1TSHRMPOGPR84 | |
| SCHEMBL3655654 | 0.78 | MPO (0.76) | SLC6A4TSHRMPOGPR84 | |
| SCHEMBL29902243 | 0.78 | MPO (0.76) | SLC6A4TSHRMPOGPR84 | |
| SCHEMBL5344966 | 0.77 | MPO (0.80) | SLC6A4TSHRMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800642-B2 | SUCH AS BENZYL-(-7,8-DIHYDRO-2,6,9-TRIOXA-3-AZA-CYCLOPENTA(A)NAPHTHALEN-8-YLMETHYL) -AMINE; FOR TREATMENT OF DRUG DEPENDENCE/ADDICTION, BIPOLAR DISORDER, PARKINSON'S DISEASE, LEVODOPA INDUCED PSYCHOSES OR DYSKINESIAS | WYETH | 2004-10-05 | — | — | US | disclosed |
| US-20020198217-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-2,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198217-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-2,6,9-trioxa-3-aza-cyclopenta[a]naphthalene | SNCA, SYNJ2, PARK7 | SLC6A4 371/4885MAPK1 2053/4885TSHR 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.